CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...
Vanguard overtakes State Street as world's largest ETF provider, with VOO emerging as largest ETF by assets. Investors flock to cost-efficient, passive investing.
Highlights,CRISPR Therapeutics has seen price adjustments from financial firms, reflecting shifts in market expectations.,The ...
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
JP Morgan analyst Matthew Boss upgraded the rating for Bath & Body Works, Inc. BBWI from Neutral to Overweight and boosted ...
New Found Gold Corp. ("New Found" or the "Company") (TSXV: NFG) (NYSE-A: NFGC) is pleased to announce the appointment of Dr.
Citi analyst Yigal Nochomovitz maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...